| Literature DB >> 27803419 |
Hiroshi Takei1, Hironari Hanaoka, Yuko Kaneko, Kunihiro Yamaoka, Aya Sasaki, Tsutomu Takeuchi.
Abstract
Polyarteritis nodosa (PAN) confined to the muscle is rare and hard to diagnose. Recently, the utility of magnetic resonance imaging (MRI) for detecting muscle involvement of PAN has been introduced. We herein report the case of biopsy-proven, refractory PAN confined to the lower limb muscles with enhanced MRI demonstrating discretely granular hyperintensities, which was contrary to previous reports. Our results, with those of previous reports, suggest that the MRI findings of muscles in PAN reflect the vessel size involved and disease severity.Entities:
Mesh:
Year: 2016 PMID: 27803419 PMCID: PMC5140874 DOI: 10.2169/internalmedicine.55.7110
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure 1.MRI findings of the lower limb muscles. (A) Coronal section. (B) Horizontal section.
Figure 2.A muscle biopsy of the femoral muscle. (A) Fibrinoid necrosis of a medium-sized vessel (Hematoxylin and Eosin staining, 400×). (B) Disruption of the elastic lamina of the vessel wall (Elastica van Gieson stain, 400×).
Figure 3.The clinical course of the patient. The x-axis indicates the date and the y-axis indicates the CRP levels (mg/dL) and (1→3) -β-D-glucan levels (pg/dL). PSL: prednisolone, mPSL: methylprednisolone, BMZ: betamethasone, IVCY: intravenous cyclophosphamide, MEPM: meropenem, ST: sulfamethoxazole/trimethoprim, MRI: magnetic resonance imaging
Clinical Features of Patients with Polyarteritis Nodosa Confined to Lower Limbs.
| Reference | Age | Gender | CK elevation | High intensities on | Contrast | Affected vessel size | Glucocrticoid | Immunosuppressants |
|---|---|---|---|---|---|---|---|---|
| Present | 69 | M | - | discretely granular | + | small | mPSL pulse | IVCY 1000mg |
| 2 | 38 | F | - | patchy | not enhanced | small | PSL 15mg | - |
| 5 | 57 | F | - | patchy | not enhanced | small | PSL 30mg | - |
| 3 | 38 | M | - | patchy | not enhanced | small and medium | PSL 20mg | - |
| 6 | 56 | M | - | diffuse | not enhanced | small and medium | PSL 30mg | - |
| 4 | 40 | M | - | patchy* | + | medium | PSL 40mg | - |
| 4 | 45 | F | - | diffuse* | not enhanced | medium | PSL 40mg | IVCY |
| 7 | 36 | F | - | diffuse | not enhanced | medium | TRI 16mg | - |
| 8 | 65 | F | + | diffuse* | not enhanced | medium | PSL 1.0mg/kg | - |
| 9 | NA | NA | - | patchy | + | NA | PSL 0.5-1.0mg/kg | - |
| 10 | 26 | M | - | diffuse* | + | NA | PSL 60mg | - |
CK: creatine kinase, mPSL: methylprednisolone, BMZ: betamethasone, IVCY: intravenous cyclophosphamide, TRI: triamcinolone, PSL: prednisolone, NA: not available * According to the description in the manuscript.